Analisa Arosemena, MD
Glaucoma Specialist · Miami Beach, FLNPI 1346346491
Payments from drug & device makers
Across 948 payments — averaging $462.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$160K
- Alcon$94K
- NEW World Medical,inc.$48K
- Nova Eye, Inc.$35K
- Aerie Pharmaceuticals, Inc.$33K
- Glaukos Corporation$23K
- plus $44K from 26 others
What the payments were for
- Consulting fees$79,50818%
- Speaking & faculty fees$279,36564%
- Travel & lodging$41,64710%
- Food & beverage$37,2528%
- Education$790%
- Gifts$620%
- Entertainment$3500%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 349 | $160,244 |
| Alcon | 186 | $93,778 |
| NEW World Medical,inc. | 77 | $48,111 |
| Nova Eye, Inc. | 19 | $35,433 |
| Aerie Pharmaceuticals, Inc. | 73 | $33,288 |
| Glaukos Corporation | 35 | $23,091 |
| Sight Sciences, Inc. | 52 | $11,228 |
| Oculus Surgical Inc. | 9 | $10,338 |
| Iridex Corporation | 4 | $8,610 |
| Ivantis, Inc | 9 | $2,670 |
| Harrow Eye, LLC | 11 | $2,656 |
| Rxsight Inc | 7 | $1,795 |
| Sun Pharmaceutical Industries Inc. | 33 | $1,612 |
| Carl Zeiss Meditec USA, Inc. | 4 | $1,408 |
| Bausch & Lomb Americas Inc. | 22 | $1,216 |
| Dompe US, Inc. | 10 | $570 |
| Thea Pharma Inc. | 11 | $495 |
| Amgen | 6 | $325 |
| Beaver-visitec International, Inc. | 1 | $262 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $213 |
| Mallinckrodt Hospital Products Inc. | 4 | $213 |
| Tarsus Pharmaceuticals, Inc. | 7 | $159 |
| Ocular Therapeutix, Inc. | 2 | $85 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $83 |
| Biotissue Holdings Inc. | 3 | $83 |
| Oyster Point Pharma, Inc. | 1 | $77 |
| Eyevance Pharmaceuticals LLC | 1 | $76 |
| Topcon Healthcare, Inc. | 1 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $36 |
| Rayner Intraocular Lenses Limited | 1 | $28 |
| Novartis | 1 | $20 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$118,861
- Rocklatan$111,623
- Rhopressa$83,461
- Ahmed Glaucoma Valve$33,027
- Kahook Dual Blade$33,027
- Streamline$29,713
- Clearpath$27,913
- SIMBRINZA$22,506
- Via360$14,292
- iDose$11,504
- OMNI(R) SURGICAL SYSTEM (US)$10,261
- XEN$9,439
- Travoprost Intraocular Implant - iDose$5,950
- Streamline Surgical System$4,814
- VEVYE$2,469
- LUMIGAN$2,064
- Hydrus Microstent$1,970
- XEN GLAUCOMA TREATMENT SYSTEM$1,560
- RXSIGHT CONTACT LENS$1,521
- RXSIGHT INJECTOR CARTRIDGE$1,521
How this compares
$438,264 in reported general payments places this provider in the 95th percentile of 31 glaucoma specialist providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 630 | $190,277 |
| CombiganBrimonidine Tartrate/Timolol | 342 | $118,919 |
| RhopressaNetarsudil Mesylate | 284 | $107,921 |
| RocklatanNetarsudil Mesylat/Latanoprost | 230 | $94,796 |
| RestasisCyclosporine | 56 | $45,625 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 245 | $26,120 |
| Alphagan PBrimonidine Tartrate | 90 | $25,902 |
| Methazolamide | 53 | $14,183 |
| VyzultaLatanoprostene Bunod | 36 | $11,110 |
| Prednisolone Acetate | 274 | $9,615 |
| VevyeCyclosporine | 12 | $8,979 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 719 | $8,720 |
| Latanoprost | 1,183 | $7,200 |
| Brimonidine Tartrate | 403 | $6,774 |
| Travoprost | 62 | $6,370 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Combigan, Restasis, Alphagan P | $160,244 | $380,7231,118 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $33,288 | $202,717514 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $1,216 | $11,11036 claims |
| NovartisIlevro, Travatan Z | $20 | $10,10830 claims |
| Harrow Eye, LLCVevye | $2,656 | $8,97912 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm | $83 | $5,88430 claims |
| AlconSimbrinza | $93,778 | $5,04625 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 31 glaucoma specialist providers in Florida.
Other glaucoma specialist in Miami Beach
- Steven VoldWinter Garden$2.5M
- Matthew BrinkPalm Beach Gardens$159K
- Yue WangMelbourne$92K
- David GreenfieldMiami$32K
- Mark WernerDelray Beach$24K
- Dan ArreazaHialeah$9K
- Daniel JewelewiczDelray Beach$9K
- Joah AliancyPort Orange$7K
- Phil AlabataCrestview$7K
- Clinton SheetsHudson$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.